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Regulation and Patterns of Endogenous
and Exogenous Gene Expression during
Differentiation of Embryonal Carcinoma
Cells
by Simonetta Astigiano,* Michael 1. Sherman,* and
Patricio Abarzua*
Embryonal carcinoma (EC) cells offer an interesting model system for evaluating differentiation because
the cells are pluripotent, thus resembling germ cells andembryonic stem cells, and because a numberofagents
have been defined that are capable ofpromoting the differentiation ofthese cells. This chapterexamines how
EC cells might be triggered to differentiate, with emphasis on retinoic acid because this compound is a po-
tent, naturally occurringinducerthat has been studied extensively in this system. The nature ofalterations
in geneexpression duringECcell differentiation is reviewedfrom theperspective ofevaluatingwhetherthese
changes arelikelytobe responsible for, ora resultof, thedifferentiation event. Finally, we considerin molecu-
larterms why EC cells, but not their differentiated derivatives, are refractory to the expression ofmany viral
genomes followinginfection. Based upon these studies, weproposethatfundamental changes in gene expres-
sion that are observed when differentiation is triggered in EC cells are likely to be due to the disappearance
or neutralization ofstrong repressor elements.
Introduction
Embryonal carcinoma(EC) cells have been extensively
usedfor several years as amodel system for the study of
differentiation. Several reviews on this subject have con-
sidered the pluripotent nature of these cells and their
similarity to early embryonic cells and germ cells (1,2),
their biology and cell biology (1-4), the nature of the
agents that can induce EC cell differentiation (4), and the
antigenic, biochemical and molecular biological markers
that characterize the differentiation event (4,5). Rather
than reiterate much ofthe material that has alreadybeen
reviewed, we have attempted to focus upon an examina-
tion of how exposure to inducers of differentiation initi-
ates changes in gene expression and how alterations in
gene expression in EC cells might trigger and/or subse-
quently imprint upon the cells a differentiated phenotype.
It is important to note at the outset that the differentia-
tion ofEC cells is a complex process which assuredly in-
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volves qualitative or quantitative alterations in the ex-
pression oflarge numbers ofgenes. The issue ofEC cell
differentiation is greatly complicated by the facts that
some ofthese cells, by virtue oftheirpluripotent nature,
can give rise to several final phenotypes (and thus prog-
ress along any of a number of differentiation pathways)
and that cells from different EC lines have their own
peculiarities, including propensity for, and patterns of,
differentiation. In fact, the EC line F9, which has prob-
ably been used more extensively than any other, differs
from other EC lines in several respects (6). Indeed, one
should exercise caution in drawing any general con-
clusions about EC cell behavior from studies with a sin-
gle cellline(somethingwhich hasbeen done all too often
with EC cells in the past).
The following section considers how exposure to an in-
ducer of differentiation, particularly retinoic acid (RA),
might be translated into triggering of new patterns of
gene expression characteristic ofthe differentiatedpheno-
type. In the subsequent section, we describe changes in
gene expression during EC cell differentiation with em-
phasis upon more recent studies that have not already
beenextensivelyreviewed. In accordance with our stated
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closely these alterations are related to the differentiation
event. In the final section, we examine how studies ofex-
ogenous (predominantly viral) gene expression might pro-
vide insight into regulation of endogenous gene expres-
sion during EC cell differentiation.
Triggering of Differentiation of
Embryonal Carcinoma Cells
EC cells can be triggered to undergo differentiation in
several ways. In early studies it was demonstrated that
physical manipulations ofthe cultures(eg., growth athigh
density or as nonadherent multicellular aggregates)
wouldresult in differentiation ofcellsfrom some EC lines
(7,8). A number of small organic molecules have been
found to promote differentiation ofthese cells, albeit with
differing potencies. Included in this list ofactive agents
are RA, retinol, other synthetic retinoids, hexamethylene-
bisacetamide (HMBA), sodium butyrate, dimethylaceta-
mide and a-difluoromethylornithine. Proposals concern-
ing mechanism of action of some of these agents have
been considered elsewhere (9-12). It is probably fair to
state that there is no unequivocal and unanimously ac-
cepted explanation ofthe molecular mechanism bywhich
any one of these agents promotes differentiation of EC
cells. In lieu ofreviewing all ofthe proposed mechanisms
ofaction for all ofthese differentiation inducers in detail,
this discussion will focus upon RA, as a great deal ofin-
formation is available about this inducer.
Considerable evidence has been presented to support
the view that the cellular RA-binding protein (CRABP)
mediates the induction of differentiation of EC cells by
RA. There is ingeneral agood qualitative correlation be-
tween the ability ofacidic retinoids to compete for bind-
ing sites on CRABP and to promote EC cell differentia-
tion (13,14). Mutant EC lines that have little or no
CRABP activity are differentiation-defective (15-17). Cell
fusion between differentiation-defective EC cells leads to
the ability to respond to RA only when the resulting
hybrids reacquire CRABP activity(18), and treatment of
CRABP-deficient EC cells with sodiumbutyrate and RA
restores CRABP activity and simultaneously causes a
significant proportion of the cells in the culture to un-
dergo differentiation (19).
Although CRABP seems to participate in RA-induced
differentiation ofEC cells, its mode ofaction remains to
be elucidated. Following early reports that the RA-
CRABP complex could interact with nuclei, it was sug-
gested that, by analogy with steroid-receptor protein
complexes, the retinoid holoprotein might influence gene
expression by direct interaction with DNA (20). In this
way, the RA-CRABP holoprotein complex could be
viewed as amaster switch, initiating a cascade ofgene ex-
pression changesleadingultimately to thefinal differen-
tiatedphenotype. However, it has become apparent that
there are significant differences between the steroid and
retinoid systems; forexample, atleast some steroidrecep-
tors appear to be resident ofthe nucleus whether or not
they possessligand (21,22), whereas the studies ofThkase
et al. (23) and others (24,25) are consistent with the view
that CRABP delivers its ligandfrom the cytoplasm to the
nucleus but does not itselfremain associated with nuclear
components. In fact, there is little evidence to suggest
that RA-CRABP or RA alone interacts directly with
DNA (26).
There have been reports ofnuclear proteins that bind
RA (27,28), but their specificities and physiological rele-
vance have notbeen established. Very recently, however,
two groups have independently identified mRNAthat en-
codes a putative and new bindingprotein for RA (which
has been called areceptor and which we shall refer to as
RetR) that is clearly a member ofthe family of nuclear
proteins that bind biological response modifiers (hor-
mones, growthfactors)inone domainand DNAinanother
(29,30). It is too early to evaluate whether this RetR in
fact serves as amaster switch because nothingis known
about the DNA sequences with which this protein spe-
cifically interacts. However, the presumed existence ofa
nuclear RetR, together with recent results concerning
CRABP, merit a reappraisal of the role of CRABP and
its involvement in the differentiation of EC cells.
The simplest and most straightforward alternative is
that CRABP could be critical for EC cell differentiation
because it must deliver RAto RetR. Thisbeingthe case,
any mutation which interfered with CRABP function
could preclude transfer of RA to the RetR and thereby
block alterations in gene expression. At the other ex-
treme, however, one could imagine a scenario, also consis-
tent with existing results, in which CRABP would play
no direct role in EC cell differentiation. Barkai and Sher-
man havereportedthat CRABPlevelsincreasewhen EC
cells are treatedwith RAforaslittle as2hr(25). Further-
more, exposure ofEC cells to RA for 4 hr or more leads
to the induction of a cytochrome P-450 enzyme system
that efficiently metabolizes RA, but only if CRABP is
present in the cells (31). There is evidence to suggest that
both ofthese events areregulatedattheleveloftranscrip-
tion(N. H. Chi, personal communication; Gubleretal., in
preparation). Ifthese transcriptional alterations are un-
derthe control ofamaster switch(e.g., RetR), thenthey
mightbe elicited inparallel to, but independently of, the
activation ofthe differentiation pathway. The absence of
CRABP transcripts and protein in differentiation-
defective mutants could thus be due to a mutation that
eliminated amaster switch function. Silencingofthe mas-
ter switch would in turn prevent the expression ofboth
the CRABPgene andthosegenesinvolved inthetrigger-
ing of the differentiation cascade.
IfCRABP were not directly involved in the differentia-
tion pathway, this could explain why other cells such as
HL-60 promyelocytic leukemia cells differentiate in re-
sponse to RA even though they appear to lack CRABP
(32). It would also lead to the prediction that one could
modulate CRABPactivityby directactionuponthatgene
withoutinterferingwiththe abilityofthe cellsto differen-
tiate in response to RA(since the RetR-triggeringmech-
anism would be unaffected). In fact, we have obtained
preliminary evidence to suggest that in some cases
CRABP activity can be restored to differentiation-
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defective (originally CRABP ) EC cells in such away as
to allow the cells to metabolize RA but not to differenti-
ate in response to the retinoid.
The preceding discussion makes clear that CRABP
could be important for differentiation of EC cells by
modulating accessibility of RA to RetR. This could be
achieved in a positive way (by transfer of RA to the nu-
cleus and RetR) and/orin a negative fashion (viapromot-
ing activation of the RA-metabolizing enzyme system,
thereby reducingcellular RAlevels). The latter function
couldbe requiredgenerally forinactivation and detoxifi-
cation of RA(9), even in cells that do not differentiate in
response to RA. Modulation of RA levels could well be
critical in embryonic cells. RA canbe a potent teratogen
(33). Also, evidence is beginning to accumulate that RA
is a morphogen during embryogenesis and that concen-
tration gradients ofthis retinoid influence tissue pattern
formation (34,35). One might, in fact, hypothesize that
CRABPandthe RA-metabolizing enzymes areprominent
in EC cells because oftheirgerm cell/embryonic cell ori-
gins. On the other hand, CRABP might notbe critical for
the differentiation of cells in which the concentration of
RA after induction ofdifferentiation would be unimpor-
tant (e.g., HL-60). Ifthe latter alternative is correct, then
there would have to be a way (not involving CRABP) in
which RA could be transported to the nucleus and/or
RetR.
Whereas we might now be in a position to learn more
about the mechanism by which RA elicits differentiation
of EC cells, it will remain for us to determine whether
otherinducers ofdifferentiation operate inidentical, par-
allel, or completely unrelated ways. In other words, is
there a single master switch or multiple approaches to
eliciting differentiation of EC cells? Retinol has no
documented ability to compete with RAfor CRABP sites
(13,15), and there is no evidence to implicate the cellular
retinol-binding protein (related to, but distinct from,
CRABP)inretinol-induced differentiation ofEC cells. It
ispossible, but notyetresolved, whetherretinol acts via
metabolic conversion to RA[for conflictingviews, see Gu-
bler and Sherman (36) and Williams and Napoli (37) and
discussion by Barkai and Sherman (25)]. Retinol does ap-
pear to compete weakly for binding to RetR (29,30).
HMBA has been proposed to act at the level of protein
kinase activity (10). Interestingly, a number of
differentiation-defective mutants selected by lack of
responsiveness to RA are also refractory to HMBA (16).
HMBA does not compete with RAforbindingto CRABP
(16) and has yet to be tested for ability to interact with
RetR.
Information is equally limited regarding mechanistic
relationships between RAandotherlowmolecularweight
inducers ofEC cell differentiation. As mentioned above,
it has been known for some time thatphysical manipula-
tions such as aggregation can influence differentiation of
EC cells; although combinations ofaggregation and small
molecules such as RA can influence the extent and direc-
tion of EC cell differentiation (38), we know essentially
nothingaboutthe molecularmechanismsgoverningsuch
physical influences. In summary, there is insufficient in-
formationtoindicate whetherornotthere is asingle mas-
ter switch for differentiation of EC cells.
Finally, the physiological relevance of all of the above
studies remains to be determined. It is clear that cells
from different EC lines differ in their propensity for
differentiation in tumorform, andto some extentwe can
mimic this differential behavior in culture (39). It has also
been demonstrated that RA administered to animals
bearing EC tumors can promote differentiation of the
cells within the tumors (40,41). However, this does little
to establish the nature ofthe endogenous agents that nor-
mally promote differentiation of EC cells in vivo in
animals not receiving dietary supplements of RA. Since
RA circulates at very low levels in animals on normal
diets(42)and since EC cells can convertretinol(which cir-
culates at much higherconcentrations)to RAverypoorly
at best (36,37), we have attempted to modulate differen-
tiation ofEC cells invivobyincreasing dietary retinol or,
conversely, byplacing animals onretinoid-deficient diets.
Although we were able to elicit increases or decreases in
circulating retinol with such dietaryregimens, we hadlit-
tle success in modifying the extent of differentiation of
cells in the EC-derived tumors (43). We must, therefore,
leave openthepossibility that otherfactors, perhaps hor-
mones, are responsible in large part for the induction of
differentiation of EC cells in vivo.
Endogenous Gene Expression and
Differentiation of Embryonal
Carcinoma Cells
Homeobox-Containing Genes
The homeobox is a 180-nucleotide protein-encoding
DNA sequence present as a highly conserved region in
sets of genes known to control embryonic development
and differentiation in Drosophila (44,45). The homeobox
sequence has also been found in the genome of several
other species, includingmammals, supportingthe notion
that homeobox-containing genes similar to those found in
Drosophila could be universally involved in controlling
certain aspects ofdevelopment anddifferentiation(46-49).
mRNs containing the antennapedia-related human
homeobox sequence Hu-1 are detected at relatively high
levels inthe humanteratocarcinomacellline NT2/D1 only
after induction ofdifferentiation by RA. It is notable that
even though the cells are presumably irreversibly dif-
ferentiated with RA, expressionofHu-1 requires the con-
tinuous presence ofthe inducer. The mouse homologMu-1
(subsequently named H24.1) was not found in this study
to be expressed in themurine cellline PSA-1 at any stage
of differentiation induced by aggregation (50).
mRNAs containing the mouse homeobox sequences
Mo-10 and m6-12 are both observed in OlAl cells (a
ouabain- and thioguanine-resistant clone of the murine
EC line P19). When aggregate cultures are induced to dif-
ferentiate eitherintoglial cellsby RA orinto cardiac mus-
cle cells by DMSO, a strong but transient increase in
Mo-10transcripts is observed. Onthe otherhand, expres-
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sion of m6-12-containing genes does not seem to be
differentiation-specific in these cells (51). The homeobox
sequence m6-12 is also expressed in F9, P19, PC13, and
EK cells. In F9 the level of expression is higher than in
the other cell lines and increases upon RA-induced differ-
entiation (52).
Recently Deschamps et al. (53) have proposed that
induction of expression of genes containing the mouse
homeobox sequences H24.1 and m6-12 in EC cell lines is
a direct effect of RA treatment and does not correlate
with cell differentiation: induction ofhighlevels ofexpres-
sion ofH24.1 and m6-12 in three different murine EC cell
lines (C17S1, PCC7.S AzaRl and PSA-1) occurs only in
the presence ofRAbut notfollowinginduction ofdifferen-
tiation by aggregation. By contrast, in Swiss 3T3 cells
treatment with RA produces an increase in the synthe-
sis ofextracellular matrix components but not in the ex-
pression ofH24.1, indicating that RA-induction ofhomeo-
box sequences is not ageneric phenomenon, but may be
restricted to EC cells. In summary, some studies of
homeobox sequence expression in EC cells provide hints
ofarelationship with differentiation, whereas otherinves-
tigations warrant cautious interpretation ofsuch results.
Structural Proteins
Components ofthe extracellular matrix appear to be in-
volved in cellular functions such as adhesion, migration,
and cell-cell interaction. Togetherwith cytoskeletal com-
ponents, the extracellular matrix strongly influences cel-
lular morphology. When EC cells are induced to dif-
ferentiate, they undergo dramatic morphological
alterations, and many changes occur concurrently in the
expression ofgenes that are associated with the produc-
tion of an extracellular matrix.
Fibronectin is aglycoprotein synthesized by a wide va-
riety of cells in vitro. Cultured EC cells synthesize
fibronectin and release it into the medium but do not re-
tain it ontheir surface. Onlyuponformation ofembryoid
bodies is there accumulation offibronectin under the en-
dodernlayer(54). In F9 cells the synthesis and secretion
offibronectin during embryoid body formation increase
on day 2, followed by a slight decrease after day 6, sug-
gestingthatfibronectin mayplay arole inthe early events
ofaggregate formation and may trigger the organization
of a basement membrane (55).
Sherman and colleagues (19,56,57) have demonstrated
that surface-associated fibronectin is often characteristic
of differentiated derivatives that result from treatment
ofEC cells with retinoids. In one ofthese studies, Sher-
man etal. (57)demonstratedthat Nulli-SCC1 cells treated
with RA display readily detected levels of surface-
associated fibronectin. Retinol, albeit a poor inducer of
differentiation ofNulli-SCC1 cells, also generates ample
amounts ofthis surface antigen. Cells from avariant line
ofNulli-SCC1 cells undergo aclearmorphological change
in response to retinol, but this phenotypic alteration is
transient: the cells revert to a typical EC-like morphol-
ogy following removal of the retinoid from the medium
(57). Thus, although it is clear from many other studies
that several differentiated cell types possess surface-asso-
ciated fibronectin, whereas undifferentiated EC cells
generally do not, the report by Sherman et al. (57) sug-
gests thatin certain EC cells, retinoids canpromote sur-
face deposition offibronectin, eventhough those cellsfail
to undergo terminal differentiation.
Type IV collagen is synthesized by undifferentiated
OC15S1 andPC13 EC cells. Followingdifferentiation into
endodermlike cells, there is suppression ofthe synthesis
ofcollagen I. However, in F9 cells the production ofcol-
lagen IV increases slightly during RA-induced differen-
tiation(55,58). The secretion oflamininandentactinis also
increased duringdifferentiation ofF9 cells(55,59). North-
ern analysis ofRNAfrom F9 cells revealed a decrease in
the level ofmRNAencodinglaminin and collagen IV 3 to
6 hr after the addition of RA and dibutyryl cAMP fol-
lowed by an increase over the next 12 to 72 hr (60). This
increase is regulated at the level of transcription (61).
Vinculin is a 130 KD protein associated with the sites
ofcontact between actin and the cell membrane and has
a role in cell attachment. Undifferentiated F9 cells show
vinculin-specific staining without fibrillar organization.
Upon differentiation into endodermal cells vinculin is or-
ganized intoplaques. This change precedes the formation
of actin-containing fibers and the appearance of keratin
(62). Undifferentiated PCC3 cells display vimentin,
whereas the endodermal derivatives differentiatingfrom
these cells show both vimentin and keratin (63,64).
Both differentiated and undifferentiated PCC3 EC cells
contain similar amounts of actin, but it is only upon
differentiation that organized microfilament bundles can
be detected (65). Based upon studies such as these, it
might be expectedthatthe amount ofactinmRNAwould
remain constant during differentiation of EC cells. We
have studied by Northern analysis the level of P-actin
mRNA in Nulli-SCC1 cells treated with 10 -6 M RA or
3 mM HMBA for increasing periods oftime (Fig. 1) (un-
published observations). We have observed with both
agents a slightreduction inthe level ofP-actinmRNA 30
min after addition of the drugs. Expression of P-actin
mRNA then returns to uninducedlevels only to decrease
once again beyond 12 hr oftreatment and to remain be-
low control values thereafter. Quantitatively, the response
to HMBA vs. RA was found to differ when results from
several experiments were averaged (the effect of HMBA
treatment wasgenerally more profound thanthat ofRA).
This might reflect the different phenotypes to which
Nulli-SCC1 cells progress when treated with the two
agents (66).
Insofar as other cytoskeletal proteins are concerned,
the network oftubulin does not show any change in rela-
tion to cell differentiation (65). When PCC3 cells are in-
duced to differentiate with HMBA, there is a large in-
crease in the synthesis of tropomyosin followed by its
association with actin bundles (67).
The lamina is a structural component of the nuclear
envelope that interactswithperipheral chromatin and the
nucleoplasmic face ofthe nuclear membrane. It plays an
important role innuclearenvelopebreakdown andforma-
tion during cell division. The lamina is formed by three
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FIGURE 1. Northern blot analysis of MT II (pR4), f3-a(
levels in Nulli-SCC1 EC cells. Inducers(10 6M RA c
were addedtofreshmedium, cultures were collected
times from addition ofinducers, and RNA was isola
(5 ug) were fractionated by electrophoresis on
forrnaldehyde gels, blotted onto nylon membranes,
with[32P]-labeled nick-translated plasmid pR4. After
the labeled probe was removed and the filters were
same way withplasmid DNAcontainingP-actin orA
lamins, A, B, and C. Differentiation of I
visceral endoderm is accompanied by the a]
lamin AandC; lamin B ispresentboth inuns
and differentiated cells (68).
IMBA.
properties asparental cells, suggestingthat the SSEA-1
haptenic site is not required for those functions.
0: F9 EC cells express the bloodgroup antigen I, but not
i, ontheirsurface. After4 daysofcultureunderconditions
S :: promotingformation ofF9 embryoid bodies, the i antigen
appears, and changes are observed in the distribution of
the I antigen in the different cell layers (73).
Epidermal growth factor (EGF) has little or no effect
APAT on theproliferation or differentiation of mouse EC cells
(e.g., PC13, OC15S1). These cellsbindvery small amounts
ofEGF. However, when they are induced to differentiate
into endodermlike derivatives, the number of EGF sur-
ACTMI face receptors increases. The differentiated cells are in-
ducedtoproliferate bythe additionofthe hormone. Treat-
ment ofthe endodermal cells with RA causes a further
increase in the numberofEGF receptors(74). Similaref-
fects have been observed with transforminggrowth fac-
torbeta(TGF-P) on PC13 and F9 cells. Differentiation of
these two cell linesleads to a 16- to40-fold increase in the
A binding of TGF-3, corresponding to an increase in the
numberofhighaffinityreceptors. The differentiated cells
are growth inhibited by TGF-P (75).
Secreted Proteins
|ptR 4 The production ofplasminogen activator is one of the
more widely used markers for EC cell differentiation.
This enzyme, which converts plasminogen into plasmin,
* is often secreted when EC cells are induced to differen-
tiate (76,77). a-Fetoprotein is synthesized and secreted
when EC cells differentiate into visceral endoderm, but
not parietal endoderm, cells (66,73,78). Apolipoprotein E
ACT1 (apoE), a protein that plays an important role in
cholesterolmetabolism, is secreted inperipheral adult tis-
sue and visceral yolk sac endoderm ofmidgestation em-
ctin, and APRT bryos. The synthesis and secretion ofapoE by F9 cells is
r3mM HMBA) correlated with the differentiation of these cells (79). , atthe dNcated ThestudyofEC cellsunderdifferentinvitro conditions
1.4% agarose- has established that EC cells condition their culture
and hybridized medium. It appears that multiple factors are produced,
autoradiography as medium conditioned by EC cells can support the
.PRTsequencest growth ofpluripotent cell lines from mouse embryos or
promote the anchorage-independent growth ofnontrans-
formed cells(80-82). Ithasbeen shown that F9 and PC13
F rcells into EC cells canproduce afactorthatis able to compete with
ppearance Of humanplateletgrowthfactor(PDGF)forbindingto mem-
lifferentiated brane receptors. Differentiation results in areduction in
the secretion of this PDGF-like factor (83).
Cell Surface Components
The SSEA-1 antigen has been very useful as a marker
for EC cell differentiation because it is no longer detect-
able regardless ofthe resulting differentiated phenotype
(69,70). Ithas been claimedthat the SSEA-1 antigen is in-
volved in cellular interactions during differentiation to en-
doderm (71). However, Rosentraus (72) isolated a mutant
cell line from F9 cells (SOTF9-11) that is deficient in
SSEA-1 binding activity and found that it exhibits the
same tumorigenic, developmental, and cell adhesion
Protooncogenes
Protooncogene expression in undifferentiated and
differentiated EC cells is detailed elsewhere in this vol-
ume (84), and so the topic will be dealt with only briefly
here.
The cellular homolog of the transforming gene of the
FBJ osteosarcoma virus, c-fos, encodes a nuclearprotein
withunknownfunctions. c-fos expression canbe induced
in a number of cell types by agents known to affect cell
growth and differentiation (e.g., TPA, growthfactors) but
29
i.- .: :- ::
...ASTIGIANO, SHERMAN, AND ABARZUA
its role in EC cell differentiation is not clear(85,86). Intro-
duction ofthe c-fos protooncogene into F9 cellsresults in
the appearance ofdifferentiation markers in some ofthe
cells. The fraction ofmorphologically altered cells remains
the same even after many passages and is not increased
by induction ofc-fos expression. This suggests that other
factor(s) as well are required for the induction of the
differentiated phenotype (87,88). In fact, when F9 cells
are induced to differentiate into parietal endoderm cells
by RA and dibutyryl cAMP, only a small increase (3-fold)
in c-fos mRNAis observed in 30min, followedby arapid
return to uninduced levels (89). In the cell line OlAl, an
increase in c-fos transcripts is evidenced during
aggregation-induced differentiation regardless ofthe na-
ture ofthe differentiatedphenotype. The increase is first
observed at 5 days after plating the aggregates, and a
peakis reached on day 7, the same day on whichmaximal
a-fetoprotein transcription can be detected (90).
Another protooncogene encoding a nuclear protein
whose expression is induced when fibroblasts and lym-
phocytes are stimulated with growth factors is c-myc.
TreatmentofF9 cellswith RAresults in a50% reduction
in the level ofc-myc mRNA after 3 hr oftreatment and
a 90% reduction after 12 hr. This early decrease has led
some authors to propose a causal relationship to cell
differentiation (91,92). However, the studies ofDean et al.
(93) suggest a correlation with the rate of proliferation
rather than differentiation. The p53 oncogene, like c-myc,
decreases during differentiation ofF9 cells in2 to 3 days.
Both c-myc and p53 appear to be posttranscriptionally
regulated in EC cells (94).
Expression of N-myc, c-src, and c-myc was studied in
four different EC cell lines(PCC7, PCC4, PCC3 and F9).
N-myc mRNA is detectable in all cell lines andits expres-
sion decreases dramatically when PCC7 cells differenti-
ate into neuronlike cells orwhen F9 cells differentiate into
parietal endoderm. InPCC7cells, the decrease in N-myc
mRNA isparalleled by an increase in c-src expression. No
c-src transcripts are detected in F9 cells, andPCC7 cells
do not express c-myc. Serum starvation did not affect the
expression of any of the protooncogenes analyzed (95).
Changes in Expression of Other Genes
With the exception of protooncogenes, whose role in
differentiation ofEC cells is stillunclear, all ofthe alter-
ations in gene expression described occurrelatively late
duringthe differentiationprocess, andtheyappear to be
characteristic ofthe differentiatedphenotyperatherthan
to be involved in the initiation ofthe differentiation pro-
cess per se. By two-dimensional gel electrophoresis,
changes in protein synthetic profiles can be detected in
Nulli-SCC1 and F9 cells as early as 3 and 6 hr, respec-
tively, after the addition of RA to the cultures (96,97).
Gudas and her colleagues (60,61,98) have analyzed cDNA
libraries from PSA-G cells (derived from the PSAl EC
line)treatedfor several dayswith RA + dibutyryl cAMP.
As mentioned above, they were able to identify cDNA
clones for collagen IV andlaminin, proteins whose levels
were already known to increase during differentiation
(60,61). They have also isolated three cDNAs that repre-
sentgenesnotyetidentified butwhose mRNAlevelsbe-
gin to increase at 12 hrfollowingexposure to RA. Levels
of mRNA are elevated 5- to 30-fold by 24 hr. This in-
creased expression is controlled at the level oftranscrip-
tion and is enhanced by dibutyryl cAMP (61).
As for the case oflaminin and collagen IV, it is likely
that modulation ofexpression ofthese unidentifiedgenes
is the consequence, rather than the cause, ofdifferentia-
tion since changes are not observed for many hours fol-
lowing the addition ofinducers (60,61). Studies from the
same laboratory have also resulted in the discovery of
eight different cDNA sequences whose levels ofexpres-
sion decrease within 12 hr of RA addition (98). One of
thesegenesencodes aheat-shockproteinthathadalready
been demonstrated to decrease duringdifferentiation (99).
It is important to stress that critical initiating events in
differentiation might equally involve increases or de-
creases in expression of particular genes (see next sec-
tion).
In an effortto identify DNA sequences that are modu-
lated at earlier stages ofEC cell differentiation, we con-
structed cDNAlibraries from Nulli-SCC1 cellstreatedfor
only24 hrwith 10-6M RA or3 mM HMBA(100,101). By
differential colony hybridization, we failed to identify
qualitative differences in the expression of mRNAs of
high or medium abundance after early timesofexposure
to differentiation inducers. We selected forfurther inves-
tigation two clones that hybridize with mRNA showing
quantitative differences during differentiation. One of
these, clone pR4, isolated from the RA-treated library
(100), hasbeenidentifiedby sequence analysisas acDNA
fortype II metallothionein(MT II). Althoughlevelsofthis
mRNA areelevated within afewhours ofexposure ofthe
cells to RA or HMBA in fresh medium (Fig. 1), much of
these early alterations are presumably a response to se-
rum factors, since the differentiation-inducing agents
alone have minimal effects on MT II mRNA levels (not
shown). The steady state levels ofMT II mRNA appear
to increase in some EC cells with culture age (unpub-
lished observations).
The second clone (pH34) that we analyzed in detail was
isolatedby U. Barkaifromthe HMBA-treatedlibrary and
hybridizes to a 650-nucleotide mRNA (101 and unpub-
lished results). Expression ofpH34 mRNAin Nulli-SCC1
cells increases modestly and transiently within minutes
ofaddition offreshmedium. However, in thepresence of
HMBA, the level ofthis mRNA decreases in 8 hr, reach-
ing barely detectable levels by 24 hr. Addition of RA
produces a smaller decrease in the level ofpH34 mRNA
(2.5-fold at 48 hr) (101). The decrease of pH34 mRNA
levels appears to be due to posttranscriptional regulation.
Thelargest openreadingframepredictedfromthepH34
cDNA sequence wouldresultin a 14kdprotein, whichwe
have, infact, observedininvitrotranslationexperiments.
The predicted amino acid sequence ofthe protein shows
no significant homologywith otherknownproteins. pH34
mRNA is abundant in Nulli-SCC1 and F9 cells, which
have arestrictedpattern ofdifferentiation, but is present
at much lower levels in P19 and PCC4 Aza1R, EC cell
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lines that differentiate more extensively. To date we have
failed to detect pH34 mRNA in non-EC cell lines oradult
and late gestation embryonic tissues. It remains to be de-
termined whether this gene plays any role in EC cell
differentiation (101; unpublished results).
Exogenous Gene Expression and
Differentiation of Embryonal
Carcinoma Cells
Itiswell documentedthatregulation ofgeneexpression
in mammalian cells canbe transcriptional, posttranscrip-
tional, translational, or posttranslational. The degree to
which each ofthese mechanisms contributestothe estab-
lishment ofthe differentiated state ofacell andthe main-
tenance ofthe differentiated phenotype remains tobe elu-
cidated. Theuse ofsmall viralgenomes asprobes to study
cellular regulatory mechanisms has provided an approach
to the problem of gene regulation in animal cells since
these viruses relyheavily onthe hosttranscriptional and
translational machinery to expresstheirgenetic program.
EC cells are restricted to infection bypapovaviruses and
ecotropic type-C retroviruses, whereas theybecome per-
missive upon differentiation. There have been extensive
and detailed studies with these viruses and EC cells be-
cause this system could shed light on mechanisms in-
volved inregulation ofviralgene expression, andbecause
important information might be gained which could pro-
mote, byanalogy, anunderstandingofhow differentiation-
specific genes are controlled.
Simian virus 40 (SV40) produces an abortive infection
in differentiated mouse cells, resulting in expression of
early viral proteins but no viral DNA synthesis or late
viral protein expression. In some cases a small fraction
ofinfected cells undergo malignant transformation (102).
By contrast, EC cells are refractory to SV40 and early
viral proteins cannot be detected following infection
(103-105). It was shown initially that the block to infec-
tion ofEC cells was not at the level ofvirus adsorption,
penetration or transport to the nucleus (103,104). More-
over, SV40 DNA extracted from infected EC cells was in-
fectious to monkey kidney cells, ruling out DNA modifi-
cation asthe blockingmechanism(106). Segal et al. (105)
reported that only a small amount of nonspliced early
viral RNA was present in SV40-infected EC cells, sug-
gesting both transcriptional and posttranscriptional reg-
ulation. Induction ofdifferentiation by RA and cAMP re-
moved the block to viral gene expression (107).
The identification and dissection ofthe SV40regulatory
sequences that act to control viral gene expression have
revealed the existence of a transcriptional enhancer re-
gion located upstream of the early promoter. This en-
hancer is typical in that it is cis acting, regulates both
homologous and heterologous promoter elements, acts
over long distances and is orientation independent
(108-110). Knowledge ofthis enhancer region made pos-
sible amore detailed molecularanalysis oftherestrictive
response ofEC cells to SV40 early gene expression. By
using DNA-mediated gene transfer techniques, Gorman
etal. (111) showed thatfollowing calciumphosphate trans-
fection ofF9 cells withpfSV3, a plasmid containing the
entire SV40genome, 30to 60% ofthe cells expressedboth
large T-antigen (T-ag) and small t-antigen (t-ag) as de-
tected by indirect immunofluorescence at 40 hrposttrans-
fection. ThelevelofT-agexpressionwas shownto depend
onthe amountofviral DNAtransfected. This dependence
on DNA concentrationoccurred onlywith viral DNAand
was not seen in differentiated cells. These data showed
that the SV40 early promoter is functional when in-
troduced into EC cells by calcium phosphate-mediated
tranfection and that there is no absolute block to its ex-
pression. Since large amounts of viral DNA are in-
troduced into individual cells bygene transfer, as opposed
to viral infection, the authors suggested thatmost likely
a negative regulatory factor(s) was being titrated out.
However, alternative interpretations are possible. Unfor-
tunately, in these studies, early viral RNA was not ana-
lyzed for efflciency of splicing.
Calcium phosphate transfection studies with homo-
logous and heterologous promoter-enhancer constructs
has shown that transcription from the SV40 early pro-
moter is enhancer-independent in undifferentiated EC
cells; i.e., the enhancerlesspromoterworks asefficiently
in transientexpression assays as the enhancer-containing
promoter. Moreover, Sassone-Corsi et al. (112) demon-
strated thatthe only sequencesupstreamfromthe SV40
earlypromoterrequired to activate transcription from a
P-globin promoter (otherwise silent in EC cells) was the
GC-rich, 21 base-pair repeat region, the TATAbox and se-
quences in between these two elements. In contrast,
differentiation restores the requirement for the SV40 en-
hancer as shown bythe lackoftranscriptionfrom the en-
hancerless promoter in F9 cells treated with RA for 4
days (111).
Ifthere is arepressorfactor(s) in EC cells as suggested
by Gorman et al. (111), itwouldbelikely to act onthe en-
hancerelement since the enhancerless promoter does not
seem to be subject to repression. This would appear con-
tradictory to the results obtainedwith the enhancer-con-
taining promoter, which is as active as the enhancerless
promoterin EC cells. However, this apparent discrepancy
could be explained by the presence in these cells of a
trans-actingfactorthat renders the SV40 earlypromoter
enhancer-independent. There is evidence to support the
existence in undifferentiated (but not differentiated) F9
cells ofa trans-acting regulatoryprotein that resembles
the adenovirus (Ad) Elaproteins(113); experiments with
other cell types suggest that Ela can repress the action
of the SV40 enhancer (114,116,117). In fact, it has now
been well documented that Ela can both activate and re-
press transcription ofseveral genes. Therefore, it is not
unreasonable to suggestthatthe SV40earlypromoter ac-
tivity in EC cells could be subject to both negative and
positive regulatory mechanisms. This Ela-like activity
couldneutralize transcriptional activationfromthe SV40
enhancerbut atthe sametime couldrenderthepromoter
enhancer-independentby trans-activation at eitherthe 21
bp repeat, the TATAbox, orboth. Thispossibility will be
considered in more detail in the following discussion.
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Further experimental evidence to support the concept
that enhancers can be targets for repression in EC cells
comes from studies with retrovirus longterminal repeat
(LTR) promoters. Retroviruses do not replicate in EC
cells. Moloneymurineleukemia virus (Mo-MLV) and mu-
rine sarcoma virus (MSV) LTRs do not function as
promoters in transient expression assays when trans-
fected into F9 EC cells (111,118). In contrast, differen-
tiated mouse cells use both viral LTRs very efficiently.
Deletion ofthe enhancer region (a 72 bp tandem repeat)
from the MSV LTR to some extent removed this repres-
sion, allowing appreciable levels oftranscription to occur
in undifferentiated F9 cells(111). Aswiththe SV40early
promoter, transcription seemed to require at least the
GC-richregionlocatedupstream oftheTATAbox, as fur-
ther deletion ofthis elementrendered the LTR transcrip-
tionally silent. Transcriptional activity of the Mo-MLV
LTR was shown to be restored byreplacingthe 72bptan-
demrepeatby aheterologous enhancer sequence known
to be active in EC cells(118). The LTRs seemto be more
effectively repressed than the SV40 earlypromoter in EC
cells since enhancer-independent transactivation does not
overcome the transcriptional blockimposed by the pres-
ence ofthe MSV enhancerregion. Furthermore, replace-
ment of the SV40 enhancer by the MSV enhancer com-
pletely abolished transcription from the SV40 early
promoter in EC cells (111,112). This repressor activity
present in EC cells appears to be saturable since cotrans-
fection with large amounts ofeither homologous or het-
erologous enhancer-containing constructs releases the
inhibition of the MSV LTR normally seen in un-
differentiated EC cells (111).
Studies on polyomavirus (Py) replication have added a
genetic dimension to viral gene expression in EC cells.
Undifferentiated EC cells are refractory to infection by
Py: both viral transcription and DNA replication are
blocked (103,104). However, the virus undergoes a full
lytic cycle in differentiated mouse cells. This hasprovided
a systemto screenforPy mutants adapted togrow in EC
cells following chronic infection of two cell lines,
PCC4-azal (PCC4) and F9 (119-124). Host-range mutants
capable of overcoming the expression block in EC cells
were isolated and found to have mutations and/or se-
quence rearrangements in the enhancer region (also in-
volved in viral DNA replication). Initially, Fujimura and
Linney (124) showed that the F9-Py mutants affected two
processes in F9 cells, oneinvolvingexpressionofPyearly
genes and a second involving viral DNA replication.
Moreover, in transient expression assays thewild-type Py
early region was minimally effective in promoting tran-
scription from heterologous genes in EC cells, whereas
DNA fragments containing Py enhancer mutants were
severalfold more efficient in stimulating transcription of
the same genes (125).
The Py enhancer region does not contain a tandemly
repeated sequence like the SV40 or LTR enhancers. This
region has been shown to include two distinctcontiguous
enhancer elements (126). The Aelement, located next to
the late transcription unit(nucleotide 5021 to nucleotide
5128 ofthe Py sequence), contains a region ofhomology
to the AdEla enhancer (Ela-core), whereas the B ele-
ment, extending from nucleotide 5128 to 5265, contains
a region ofhomology to the SV40 enhancer (SV40-core).
Both elements work independently in promoting tran-
scription from heterologousgenes in transfection experi-
ments, although with different cell specificities. For in-
stance, element A provided a 3-fold enhancement ofthe
a-2-collagenpromoterthanelement B in3T6cells. By con-
trast, in PCC3 EC cells, the B element showed the same
efficiency as in fibroblasts, whereas element A was
several-fold less efficient (126). In summary, host-range
mutants adapted togrowinF9 cellsalwaysexhibitmodifi-
cations inthe B element, usually asinglebasepairchange
(AT to GC at position 5233), often followed by a tandem
duplication also containing the point mutation. On the
other hand, PCC4-adapted mutants lack the B element
and contain a duplicated A element.
Two groups have recently demonstrated that the Ela
products ofAd5 and Adl2 repressed expressionfrom the
Py early promoter in 293 (a human transformed cell line
that constitutively expresses low levels of the Ela pro-
teins) or HeLa cells (114,127,128). The target of repres-
sion was again shown to be the enhancer region. Unex-
pectedly, Ela proteins could even repress enhancer
mutants which have overcome block to expression in F9
and PCC4 EC cells (128), although other studies suggest
that the dosage ofElamustbe highforrepression ofen-
hancer mutants to occur (127). Thken together these
resultsand studies withothercelllines(127) suggestthat:
a) the Py early promoter is more sensitive to repression
by Ela than is the SV40 promoter; b) Py enhancer mu-
tants adapted to growth in EC cells require elevated
levels ofthe Elaproteinstoberepressed; andc) Elapro-
teins more efficiently trans-activate the enhancerless
SV40 promoter than the Py promoter.
Whether the trans-activator and repressor activities
present in EC cells reside in the same or different pro-
tein molecule(s) remains to be determined. However, it is
possible to construct a scenario that could explain how a
cellular Ela-like activity, specific to undifferentiated cells,
could result in the observed transcriptional regulation of
the SV40 and Py earlypromoters and retroviral LTRs in
EC cells. Itislikely thatthe SV40 enhanceris eithernot
repressed or only modestly repressed by the low levels
of Ela-like proteins existing in EC cells. Transcription
from the early SV40promoterwouldthus be expected to
be weakly trans-activated by this Ela-like factor(s) in an
enhancer-independent manner by interaction, either
directly orindirectly, with sequenceslocatedbetweenthe
enhancer and the start site for the early mRNA.
Upon differentiation, the Ela-like activity declines to
unmeasurable levels and could be replacedby a new fac-
tor(s) that trans-activate(s) the SV40 promoter in an
enhancer-dependentfashion. Thismodel seems tobe con-
tradictory to the DNA concentration dependency for
large T-ag expression observed by Gorman et al. (111).
These authors suggested that a negative regulatory fac-
tor(s) was beingtitrated out. However, otherinterpreta-
tions are possible. For instance, apositively acting tran-
scription factorcouldbepresent atlimitinglevels and/or
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be of low affinity such that no transcription would take
place until a threshold level is reached. Alternatively, as
shown earlier, splicingcouldbe playingamajorrole in the
block to SV40 early gene expression in EC cells, and no
mature, correctly splicedT-agmRNAwouldbe observed
until the rate of transcription reached a threshold. Two
observations support the latter explanation. First,
concentration dependency was only observedwhen Gor-
man et al. used viral DNA and measured expression of
T-ag. Second, intransient expression assays where splic-
ingwas notrequired forproduction ofmature functional
mRNA, the enhancerless SV40 early promoter was tran-
scriptionally indistinguishable from the enhancer-
containingpromoter. Thus, further experiments that ad-
dress this question ofsplicing in SV40 early expression
in EC cells are required before more definitive conclu-
sions can be drawn.
In contrast to SV40, retrovirus LTRs andthe Py early
promoter seem, overall, to be subject to negative regula-
tion in EC cells by repression targeted to the enhancer.
The repressorfactor(s)islikely tobe an Ela-like activity.
Repression overrides enhancer-independant trans-activa-
tion ofthese promoters. This is consistent with the obser-
vationthatthe Pyearlypromoterismore sensitive to Ela
repression than the SV40 promoter and that the MSV
LTR enhancer suppresses enhancer-independent trans-
activation of the SV40 early transcription unit.
In the case ofthe Pypromoter there is evidence to sug-
gest that the B enhancer element is the target ofrepres-
sion. Forexample, Py mutants able to growin PCC4 EC
cells always lackthe B enhancerbutpossess aduplicated
A enhancer. On the other hand, F9 Py mutants always
contain an altered and, in many cases, duplicated B en-
hancer. By contrast, theAelementisneverdeletedin F9
orPCC4 EC mutants; thus, it is unlikely to be the target
ofrepression. Rather, once strongrepression ofthe early
promoter is released by deletion of the B element in
PCC4-adapted mutants, a second site for a weak and/or
low abundance trans-activatingfactor(actingonthe Aele-
ment) is created that can now synergize with enhancer-
independent trans-activation, allowing more efficient ex-
pression of the Py promoter.
F9-adapted Py mutants seem to follow a different
strategy to overcome the block to expression, perhaps
reflecting subtle differences in gene expression when
compared to other EC cells. Whereas negative regulation
maybe abolishedbythepoint mutation, itisunlikely that
such achange wouldbe so specific(always atthe samepo-
sition) and so often duplicated onlyto release suppression.
Thus, it is plausible to propose that such an alteration cre-
ates anew sequence motifthat cannowfacilitate thebind-
ing of a positively acting factor present in F9 cells (but
probably inactive or absent in PCC4 cells).
Anuclearfactor has recently been described to be pres-
ent in F9 cells that can discriminate between the wild-
type and a F9 Py mutant enhancer. This protein factor,
which can bind to the mutant sequence but very poorly
to the wild-type, ispresent in avariety ofcells, including
F9 cells and differentiated derivatives (129). This is in
good agreement with the observation that F9 Py en-
hancer mutants are always more efficient than the wild-
type Py enhancerinpromotingtranscriptionfrom heter-
ologous promoters, not only in F9 cells but also in a vari-
ety ofdifferentiated cells, including RA-treated F9 cells
(125,126). In addition, F9 Py mutants with tandem dupli-
cations containing the point mutation are at least twice
as efficient as mutants without it (125). Since F9 Py mu-
tants are still restrictedin PCC4 cells, this lends support
to the idea that the single base pair change inelement B
does not only release repression. Instead, it is possible
that the new sequence motifcreated allows the positively
actingfactor described above to compete out the repres-
sor, overcoming the block to expression. In contrast,
PCC4-adapted Py mutants can still be expressed in F9
cells, although at low efficiency.
That the Py early promoter is subject to negative reg-
ulation in EC cells has also been suggested by experi-
ments with protein synthesis inhibitors. Cremisi and
Babinet(130) showedthattreatment ofPyinfected-PCC4
cells with low doses of cycloheximide for 24 hr allowed
substantial expression of T-ag (25- to 60-fold increase),
suggesting the presence of a short-lived repressor pro-
tein(s). Moreover, cycloheximide treatment ofPCC4 cells
infected with a PCC4-adapted mutant showed only a mar-
ginal effect (3- to 10-fold increase) on T-ag expression,
again suggesting that the maintarget ofrepression is the
B enhancer.
Transcriptional regulation appears to be the major
mechanism used by EC cells to restrict expression of
papovaviruses and ecotropic type-C retroviruses; how-
ever, it is increasingly evident that in many cases viral
transcription units are not completely silent inthese cells,
strongly suggesting additional control mechanisms in vi-
rus suppression. For example, early studies with retro-
virus-infected EC cells showed that following infection
andintegration, the provirus became heavilymethylated
(131). This led to the suggestion that DNA methylation
was responsible for the block to expression. However, it
waslaterdemonstratedthatmethylation wasalate event,
suggesting an effect of, rather than the cause for, lack of
expression(132,133). Inaddition, methylatedprovirusge-
nomes could not be activated even after induction of
differentiation, asituation knownto restore viruspermis-
siveness.
Recent studies onretrovirus restrictioninEC cellshave
uncovered some new information that could shed some
light on other control mechanisms. Infection ofEC cells
with retroviruses leads to integration of proviral DNA
into thegenome at normal levels, butviral-specific RNA
is detected atless than 1% the level ofinfected NIH/3T3
cells(131,132). However, infection ofEC cellswith recom-
binant retroviruses containing the selectable neomycin
phosphotransferase gene results in rare colonies that are
resistant to the antimetabolite G418(134-136). Studies of
these host-range variants have indicatedthatproviruses
can overcome suppressionby two different mechanisms:
integrationat ornearcis-actinghost DNA sequences and
mutations in the viral control elements. Several
proviruses whose expression is mediated by 5'-flanking
host sequences have been isolated. These studies have
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shown that there are a limited number of chromosomal
positions inthe cellulargenome ofEC cells that allows vi-
rus expression (136). Not surprisingly, one study led to
the isolation ofone oftheseflanking sequences whichwas
shown to behave as an enhancer element in transfection
assays (137).
Using the same approach, Barklis et al. (136) isolated
a Mo-MLV host-range variant with a single point muta-
tion in the 5'untranslated region ofthe virus(within, the
tRNAprimerbinding region). In contrast to Py, no host-
range variants with single base pair changes within the
LTR enhancer have been isolated. However, a mutant of
MSV, the myeloproliferative sarcoma virus (MPSV),
which has been shown to be efficiently expressed in F9
EC cells (but not in PCC4 cells), contains several specific
point mutations within the U3 region ofthe LTR when
compared to the MSVand Mo-MLV LTRs(138-141). Most
of these mutations are clustered in or around the en-
hancer region (142). Additional changes and rearrange-
ments are required for expression in PCC4 cells (143).
Thus, morethan asingle basepairchange within the LTR
seems to be required to alter the host-range specificity
ofretroviruses in EC cells, and this explains the difficulty
in isolating such mutants by this procedure.
The host-range mutant with the single basepairchange
within the tRNA primer-binding site has been shown to
be expressed in both F9 and PCC4 cells (144). This mu-
tation enhances the level of stable RNA present in F9
cells by about 10-fold, whereas ithas no effectin NIH/3T3
cells. How this mutation actually increases the levels of
RNA ispresently unknown. Because it maps outside the
LTR, it is temptingto speculate that aposttranscriptional
mechanism is involved. Forinstance, the 10-fold enhance-
ment of stable neomycin phosphotransferase mRNA
(transcribed from the gene driven by the viral mutant
LTR) contrasts with a 1000-fold stimulation in the forma-
tion ofG418-resistant colonies in F9 andPCC4 cells(144).
Whetherthe extent ofselectable gene expression is now
close to threshold levels or whether the point mutation
affects, for example, the efficiency oftranslation, are is-
sues that require resolution before further speculation is
warranted. Nevertheless, it should be pointed out that
there are precedents for the involvement of 5'-un-
translated sequences in the regulation ofretrovirus gene
expression (145,146). Whatever the mechanism of regu-
lation might be, it does not seem to involve tRNApro
primerbindingbecause the MPSV 5'noncoding sequence
does not differ from the Mo-MLV sequence within the
tRNA binding region itself, but in sequences close to it.
However, MPSV is as active as the B2 mutant in trans-
ducing neomycin resistance in EC cells (144). The cor-
responding Mo-MLV and MSV 5'-untranslated regions
are inactive. Since the recombinant retroviruses used in
these studies lack most, but not all, ofthe viralfunctions,
it is not clearwhether aviral or a cellular factormediates
control at this site.
From all of the above studies it is apparent that EC
cells are unusual in that they can actively suppress ex-
pression from otherwise strongviral transcription units.
In some cases (e.g., Py, LTRs), transcriptional enhancers
in differentiated cells actually become the target of
repression in EC cells. In other instances (e.g., the SV40
early promoter), suppression oftranscription in EC cells
is not absolute, although viral proteins are not produced,
suggestingposttranscriptional regulation as yet another
mechanism responsible for virus suppression. Upon
differentiation ofEC cells, theblockto expression ofthese
viral genomes is removed and their enhancers become
fullyfunctional. Since no viral proteins are required in the
early stagesofvirus expression, repression mustbe medi-
atedby cellular factor(s) present in EC cells but either ab-
sent (or at low abundance) or inactive in differentiated
cells. In addition, it is likely that new factor(s) required
for enhancer function are induced during differentiation
(147).
Endogenous differential gene expression could be simi-
larly regulated by EC cells. In other words, differentia-
tion-specific genes could be maintained in a state of
repression in undifferentiated EC cells by specific nega-
tive regulatory factor(s), perhaps the same ones that sup-
press viral gene expression. Ifthis is the case, how, then,
is the cascade of events leading to differentiation trig-
gered? One can imagine that either repression of nega-
tive factor(s) or induction ofnew activator(s)would serve
to overcome or reverse the effect ofthe repressor mole-
cule(s). Recent evidence obtained by Montano and Lane
(148) strongly suggeststhatitisthe repression ofcertain
genes thattriggers irreversible differentiation ofEC cells.
These authors showed originally thattransfection ofEC
cells with plasmids encoding Ad5 Elagene products un-
derwent radical morphological and biochemical changes
characteristic ofthe differentiated state inducedby treat-
ment with RA. However, they then demonstrated that a
plasmid encoding the Ela enhancer-dependent repressor
activity, but lacking the trans-activating activity, induced
the same changes as the complete Ela coding region.
Further support for the repressor hypothesis derives
from ourobservation that exposure ofEC cells to low con-
centrations of cycloheximide [a treatment which allows
substantial expression of Py T-ag in Py-infected PCC4
cells (130)], results in differentiation of a significant
proportion of cells in the cultures (P. Abarzu'a, unpub-
lished observations). We propose, therefore, that EC cells
are maintained in the undifferentiated state by the pres-
ence of one or more short-lived repressor proteins. We
also feel it likely that viral genes are regulated in a nega-
tive fashion in undifferentiated EC cells because their
regulatory sequences share elements in common with
genes selectively expressed in differentiated cells.
In view ofthe close relationship between EC cells and
germ cells(3), itispossible thatrefractoriness ofEC cells
to viral gene expression reflects an evolutionary mecha-
nism for minimizing virus infection ofgerm cells (which
in turn would serve to regulate the introduction into the
species of new genetic material).
It seems reasonable to assume from the studies
reviewed inthis sectionthat in bothviral and cellular sys-
tems, repressors and trans-activatingfactorswill compete
and interact with differing affinities and specificities for
anygenetic control region, allowing a delicate differential
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control ofgene expression. In this context, the stem cell
phenotype of EC cells can be thought of as a dynamic
equilibrium maintained by the interaction (and relative
abundance) of both positive and negative regulatory
molecules with specific sequence motifs withinregulatory
elements of critical genes. Inducers of differentiation
could then readily be envisaged to act by disturbing this
equilibrium as a consequence ofeither direct or indirect
changes in gene expression.
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